George Lee Southard

US Patent:

7976847, Jul 12, 2011

Filed:

Jan 13, 2005

Appl. No.:

10/586209

Inventors:

Jeffrey L. Southard - Lenexa KS, US
George L. Southard - Sanibel FL, US

Assignee:

VasoGenix Pharmaceuticals, Inc. - Lenexa KS

International Classification:

A61K 38/23
A61K 9/52

US Classification:

4241981, 424489

Abstract:

The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.

US Patent:

20090023643, Jan 22, 2009

Filed:

Jan 13, 2005

Appl. No.:

10/586036

Inventors:

Jeffrey L. Southard - Lenexa KS, US
George Lee Southard - Sanibel FL, US

Assignee:

VasoGenix Pharmaceuticals, Inc. - Lenexa TX

International Classification:

A61K 38/17
A61P 9/00

US Classification:

514 12

Abstract:

This invention relates to methods of treating acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention also relates to preventing an acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention further relates to compositions of CGRP for use in such methods. This invention also relates to the use of calcitonin gene related peptide in the manufacture of medicament for treating or preventing an acute myocardial infarction in a subject or for treating a subject suspected of having an acute myocardial infarction.

US Patent:

20090023644, Jan 22, 2009

Filed:

Jan 13, 2005

Appl. No.:

10/586037

Inventors:

Jeffery L. Southard - Olathe KS, US
George Lee Southard - Sanibel FL, US

International Classification:

A61K 38/16
A61P 9/00

US Classification:

514 12

Abstract:

The present invention provides methods of treating and preventing mortality associated with heart failure and renal insufficiency in a Stage B, C, or D heart failure patient, and for improving quality of life by providing improved methods of administering a therapeutically effective amount CGRP. One method comprise administering between about 50 and about 500 ng/min of CGRP for a time between 30 minutes and 8 hours per day for as many days as needed to provide symptomatic relief, prevent exacerbation of symptoms, and/or prevent and/or delay progression of the disease state of heart failure in said patient. The therapies can be administered on an outpatient or inpatient basis.

US Patent:

20110150980, Jun 23, 2011

Filed:

Nov 18, 2010

Appl. No.:

12/949565

Inventors:

George Lee Southard - Sanibel FL, US
Jeffrey Lee Southard - Olathe KS, US

Assignee:

VasoGenix Pharmaceuticals, Inc. - Lenexa KS

International Classification:

A61K 38/17
A61K 9/14
A61K 9/127
A61P 9/04
A61P 25/06
A61P 13/12
A61P 9/12
A61P 9/00
A61P 9/10
A61P 15/00

US Classification:

424450, 424484, 424486, 514 213, 514 164, 514 177, 514 154, 514 157

Abstract:

Sequence modified calcitonin gene related peptide (CGRP) compounds are useful for treating heart failure, stroke, hemorrhagic shock, or migraine, improving renal function, preventing or delaying the advancement of heart failure into advanced stages, treating angina, controlling pulmonary hypertension, counteracting ischemia due to a myocardial infarction, preventing vasospasms during angioplasty, preventing reocclusion of blood vessels during and/or after angioplasty, stent insertion, or the implantation of a vascular grafts, and for treating male impotence and female sexual arousal disorder.

US Patent:

20110244005, Oct 6, 2011

Filed:

Jun 16, 2011

Appl. No.:

13/162285

Inventors:

Jeffrey L. Southard - Olathe KS, US
George L. Southard - Sanibel FL, US

Assignee:

VasonGenix Pharmaceuticals, Inc. - Lenexa KS

International Classification:

A61K 9/14
A61K 38/02
A61P 9/10

US Classification:

424400, 514 151

Abstract:

The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.

US Patent:

45900612, May 20, 1986

Filed:

May 10, 1985

Appl. No.:

6/732651

Inventors:

George L. Southard - Fort Collins CO

Assignee:

Vipont Laboratories, Inc. - Fort Collins CO

International Classification:

A61K 726
A61K 3578

US Classification:

424 71

Abstract:

Benzo-c-phenanthridine salts, either pure salts or salts precipitated form extracts of plants selected form the group consisting of Sanguinaria canadensis, Macleaya cordata, Corydalis sevctvozii, C. ledebouni, Chelidonium majus, and mixtures thereof, are effective agents for disclosing plaque in the oral cavity under long wavelength ultraviolet light.

US Patent:

53688597, Nov 29, 1994

Filed:

Jun 29, 1993

Appl. No.:

8/084777

Inventors:

Richard L. Dunn - Fort Collins CO
Arthur J. Tipton - Fort Collins CO
George L. Southard - Fort Collins CO
Jack A. Rogers - Fort Collins CO

Assignee:

Atrix Laboratories, Inc. - Fort Collins CO

International Classification:

A61F 200

US Classification:

424426

Abstract:

Methods are described for assisting the restoration of periodontal tissue in a periodontal pocket and for retarding migration of epithelial cells along the root surface of a tooth. The methods involve placement of an in-situ forming biodegradable barrier adjacent the surface of a tooth. The barrier is microporous and includes pores of defined size. The barrier can include a biologically active agent.

US Patent:

50770497, Dec 31, 1991

Filed:

Jul 24, 1989

Appl. No.:

7/384416

Inventors:

Richard L. Dunn - Fort Collins CO
Arthur J. Tipton - Fort Collins CO
George L. Southard - Fort Collins CO
Jack A. Rogers - Fort Collins CO

Assignee:

Vipont Pharmaceutical, Inc. - Fort Collins CO

International Classification:

A61F 200

US Classification:

424426

Abstract:

Methods are described for assisting the restoration of periodontal tissue in a periodontal pocket and for retarding migration of epithelial cells along the root surface of a tooth. The methods involve placement of an in-situ forming biodegradable barrier adjacent the surface of a tooth. The barrier is microporous and includes pores of defined size. The barrier can include a biologically active agent.